50 results on '"Pantarotto, Jason"'
Search Results
2. Ontario Health-Cancer Care Ontario Re-Irradiation Symposium Webinar: A Provincial Initiative to Enhance Quality and Safety in Radiation Treatment
3. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
4. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
5. Clinical Specialist Radiation Therapist in Palliative Radiation Therapy: Report of an Orientation, Training, and Support Program
6. Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)
7. Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers
8. 302 Health Care System Factors Associated with Receipt of Treatment and with Treatment Intent in Stage Iii Non-Small Cell Lung Cancer: A Population-Based Study in Ontario
9. 221 Survey on the Structure of Inpatient Care Provided by Radiation Oncologists in Canada
10. 297 Population Analysis of SABR/SRS for the Treatment of Metastatic Cancer in a Jurisdiction of 15 Million People
11. Breast Metastasis From Primary Lung Cancer and its Association with Ablative Radiotherapy: A Case Report
12. Radical Treatment of Stage II Non–small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes
13. Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
14. Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program
15. A Clinical Consensus Approach to Developing a New Funding Model for Radiation Services in Ontario
16. Pan-Canadian consensus recommendations for proton beam therapy access in Canada
17. 9: Trends in Radiotherapy Fractionation in Ontario From 2011/12 to 2020/21 for the Major Disease Sites and the Impact of COVID19
18. Ablative vs. Non-Ablative Radiotherapy in Palliating Locally Advanced Pancreatic Cancer: A Single Institution Experience and a Systematic Review of the Literature.
19. Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases
20. Developing Radiation Treatment Protocols to Support the Transition to a Quality Based Procedure
21. Cancer Clinic Redesign: Opportunities for Resource Optimization
22. Cancer Clinic Redesign: Opportunities for Resource Optimization
23. 130: Radiation Oncologist Consultations Prior to Radical Prostatectomy in Ontario: Disparities and Implications for Health Human Resource Planning
24. 102: Treatment Planning During the Pandemic – Did Flexible Work Arrangements Make us More Efficient?
25. 142: Virtual Care Uptake in Radiation Medicine: Lessons Learned from the COVID-19 Pandemic
26. 149: Do Virtual Ro Consults Expedite Treatment? Another Tale from the COVID-19 Pandemic
27. 146: COVID-19 Pandemic Impact on Radiation Treatment Delivery Metrics
28. 114: Quality Assurance of Radiotherapy During the COVID-19 Pandemic: Impact on Peer Review in 14 Regional Cancer Centres Across Ontario
29. Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.
30. Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy
31. Adrenal oligometastasis cured with stereotactic ablative radiotherapy
32. 39: Impact of Smoking Status and Pack Year History on Outcomes of Early Stage Non-Small Cell Lung Cancers Treated with Stereotactic Ablative Radiotherapy
33. A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases
34. 25 Stereotactic Body Radiation Treatment of Synchronous Early Stage Non-Small Cell Lung Cancers
35. 113 Outcome Comparison Between Early Stage Adenocarcinoma and Squamous Cell Carcinoma Lung Cancers Treated with Stereotactic Body Radiation Therapy
36. Feasibility, detectability and clinical experience with platinum fiducial seeds for MRI/CT fusion and real-time tumor tracking during CyberKnife
37. Validating impact of pretreatment tumor growth rate on outcome of early‐stage lung cancer treated with stereotactic body radiation therapy.
38. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial
39. Mo1307 HOW GOOD IS EUS GUIDED FIDUCIAL PLACEMENT FOR TARGETED CYBERKNIFE RADIOTHERAPY?
40. Mo1301 NOVEL PLATINUM FIDUCIAL SEEDS MADE IN HOUSE AND WIRE PUSH DELIVERY METHOD
41. Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy
42. Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program
43. P1.05-069 Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes
44. 221: Radiation Dose Mapping of the Stomach in Trimodality Therapy for Esophageal Cancer
45. 236: Validity of Specific Growth Rate in Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy (SBRT)
46. CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
47. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists
48. Lung cancer diagnosis transformation: Aligning the people, processes, and technology sides of the learning system.
49. Abstract 763: Implications of resistance patterns with NSCLC targeted agents
50. Feasibility, detectability and clinical experience with platinum fiducial seeds for MRI/CT fusion and real-time tumor tracking during CyberKnife® stereotactic ablative radiotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.